Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...

Oral Hypoglycemic Agents: Sulfonylureas

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...

Depolarizing Blockers: Pharmocokinetics

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Prognostic Implications of Left Ventricular Ejection Fraction Improvement in Patients with Heart Failure with Reduced and Mildly Reduced Ejection Fraction.

Acta Cardiologica Sinica·2026

Same author

In-Hospital Implementation of Evidence-Based Medications is Associated with Improved Survival in Diabetic Patients with Acute Coronary Syndrome - Data from TSOC ACS-DM Registry.

Acta Cardiologica Sinica·2018

Same author

The 2017 Focused Update of the Guidelines of the Taiwan Society of Cardiology (TSOC) and the Taiwan Hypertension Society (THS) for the Management of Hypertension.

Acta Cardiologica Sinica·2017

Same author

Monascus Adlay and Monacolin K Attenuates Arterial Thrombosis in Rats through the Inhibition of ICAM-1 and Oxidative Stress.

Kidney & blood pressure research·2016

Same author

Syncope Due to Impending Cardiac Tamponade in Hashimoto's Thyroiditis.

Acta Cardiologica Sinica·2016

Same author

2015 guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the management of hypertension.

Journal of the Chinese Medical Association : JCMA·2014

Search research articles

Related Experiment Video

Updated: Jul 15, 2026

Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats

Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats

Published on: February 14, 2022

Sulpiride induced torsade de pointes.

Bien-Hsien Huang, Chih-Ping Hsia, Chung-Yin Chen

International Journal of Cardiology

|April 6, 2007

Summary

Antipsychotic medications can prolong the QT interval, increasing torsade de pointes risk. Sulpiride caused this dangerous heart rhythm in a patient, highlighting the need for close monitoring.

Area of Science:

Cardiology
Psychiatry
Clinical Pharmacology

Background:

Antipsychotic medications are frequently associated with cardiac adverse events, including QT interval prolongation and potentially fatal torsade de pointes.
Identifying specific agents and risk factors is crucial for patient safety in psychiatric care.

Observation:

A 69-year-old female presented with syncope, revealing torsade de pointes and a significantly prolonged QT interval (QTc=680 ms) on electrocardiogram.
Detailed drug history identified sulpiride as the causative agent responsible for the observed cardiac event.

Findings:

Discontinuation of sulpiride led to a rapid normalization of the QT interval (QTc=420 ms), confirming its role in the torsade de pointes episode.
This case underscores the proarrhythmic potential of sulpiride, particularly concerning its effects on cardiac repolarization.

More Related Videos

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

Point of Care Transcranial Color-Coded Duplex Ultrasound of the Middle Cerebral Artery

Point of Care Transcranial Color-Coded Duplex Ultrasound of the Middle Cerebral Artery

Published on: August 9, 2024

Related Experiment Videos

Last Updated: Jul 15, 2026

Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats

Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats

Published on: February 14, 2022

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

Point of Care Transcranial Color-Coded Duplex Ultrasound of the Middle Cerebral Artery

Point of Care Transcranial Color-Coded Duplex Ultrasound of the Middle Cerebral Artery

Published on: August 9, 2024

Implications:

Clinicians must exercise vigilance when prescribing sulpiride, closely monitoring patients for signs of QT prolongation and cardiac arrhythmias.
Concurrent use of sulpiride with other medications known to affect the QT interval, such as certain antidepressants, warrants heightened caution and careful risk-benefit assessment.